QQQ   311.72 (+3.59%)
AAPL   150.82 (+3.71%)
MSFT   264.60 (+4.69%)
META   188.77 (+23.28%)
GOOGL   107.74 (+7.28%)
AMZN   112.91 (+7.38%)
TSLA   188.27 (+3.78%)
NVDA   217.09 (+3.66%)
NIO   11.96 (-1.16%)
BABA   109.74 (-2.73%)
AMD   88.31 (+4.34%)
T   20.28 (+0.50%)
MU   63.17 (+0.91%)
F   14.32 (+3.84%)
CGC   3.14 (+1.95%)
GE   83.94 (+1.97%)
DIS   113.21 (+3.49%)
AMC   6.08 (+6.48%)
PFE   44.34 (+0.84%)
PYPL   86.96 (+4.88%)
NFLX   366.89 (+1.35%)
QQQ   311.72 (+3.59%)
AAPL   150.82 (+3.71%)
MSFT   264.60 (+4.69%)
META   188.77 (+23.28%)
GOOGL   107.74 (+7.28%)
AMZN   112.91 (+7.38%)
TSLA   188.27 (+3.78%)
NVDA   217.09 (+3.66%)
NIO   11.96 (-1.16%)
BABA   109.74 (-2.73%)
AMD   88.31 (+4.34%)
T   20.28 (+0.50%)
MU   63.17 (+0.91%)
F   14.32 (+3.84%)
CGC   3.14 (+1.95%)
GE   83.94 (+1.97%)
DIS   113.21 (+3.49%)
AMC   6.08 (+6.48%)
PFE   44.34 (+0.84%)
PYPL   86.96 (+4.88%)
NFLX   366.89 (+1.35%)
QQQ   311.72 (+3.59%)
AAPL   150.82 (+3.71%)
MSFT   264.60 (+4.69%)
META   188.77 (+23.28%)
GOOGL   107.74 (+7.28%)
AMZN   112.91 (+7.38%)
TSLA   188.27 (+3.78%)
NVDA   217.09 (+3.66%)
NIO   11.96 (-1.16%)
BABA   109.74 (-2.73%)
AMD   88.31 (+4.34%)
T   20.28 (+0.50%)
MU   63.17 (+0.91%)
F   14.32 (+3.84%)
CGC   3.14 (+1.95%)
GE   83.94 (+1.97%)
DIS   113.21 (+3.49%)
AMC   6.08 (+6.48%)
PFE   44.34 (+0.84%)
PYPL   86.96 (+4.88%)
NFLX   366.89 (+1.35%)
QQQ   311.72 (+3.59%)
AAPL   150.82 (+3.71%)
MSFT   264.60 (+4.69%)
META   188.77 (+23.28%)
GOOGL   107.74 (+7.28%)
AMZN   112.91 (+7.38%)
TSLA   188.27 (+3.78%)
NVDA   217.09 (+3.66%)
NIO   11.96 (-1.16%)
BABA   109.74 (-2.73%)
AMD   88.31 (+4.34%)
T   20.28 (+0.50%)
MU   63.17 (+0.91%)
F   14.32 (+3.84%)
CGC   3.14 (+1.95%)
GE   83.94 (+1.97%)
DIS   113.21 (+3.49%)
AMC   6.08 (+6.48%)
PFE   44.34 (+0.84%)
PYPL   86.96 (+4.88%)
NFLX   366.89 (+1.35%)
NASDAQ:AERI

Aerie Pharmaceuticals - AERI Stock Forecast, Price & News

Notice: This company has been marked as potentially delisted and may not be actively trading.
Add
Compare
Today's Range
$15.25
$15.25
50-Day Range
$15.18
$15.25
52-Week Range
$4.81
$15.37
Volume
600 shs
Average Volume
974,748 shs
Market Capitalization
$753.61 million
P/E Ratio
N/A
Dividend Yield
N/A
Price Target
$16.90

Aerie Pharmaceuticals MarketRank™ Forecast

Analyst Rating
Hold
2.00 Rating Score
Upside/​Downside
10.8% Upside
$16.90 Price Target
Short Interest
N/A
Dividend Strength
N/A
Sustainability
-2.26
Upright™ Environmental Score
News Sentiment
N/A
Insider Trading
N/A
Proj. Earnings Growth
Growing
From ($2.02) to ($1.18) Per Share

Overall MarketRank

MarketRank is calculated as an average of available category scores, with extra weight given to analysis and valuation.

1.51 out of 5 stars

Medical Sector

949th out of 1,030 stocks

Biological Products, Except Diagnostic Industry

156th out of 169 stocks


AERI stock logo

About Aerie Pharmaceuticals (NASDAQ:AERI) Stock

Aerie Pharmaceuticals, Inc., a pharmaceutical company, focuses on the discovery, development, and commercialization of ophthalmic therapies for open-angle glaucoma, dry eye, diabetic macular edema, and wet age-related macular degeneration in the United States. Its products include Rhopressa, a once-daily eye drop to reduce elevated intraocular pressure (IOP) in patients with open-angle glaucoma or ocular hypertension; and Rocklatan, a once-daily fixed-dose combination of Rhopressa and latanopros to reduce IOP to treat patients with open-angle glaucoma or ocular hypertension. The company also develops AR-15512 to treat signs and symptoms of dry eye; and AR-1105 and AR-14034 SR sustained-release implants focused on retinal diseases. It has a collaborative research, development, and licensing agreement with DSM Biomedical. Aerie Pharmaceuticals, Inc. was incorporated in 2005 and is headquartered in Durham, North Carolina.

Receive AERI Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Aerie Pharmaceuticals and its competitors with MarketBeat's FREE daily newsletter.

AERI Stock News Headlines

Alcon Inc. (ALC) Q3 2022 Earnings Call Transcript
Top Innovation Stock
Today's stock market report features an AI Robotics tech stock with a $4 million order backlog.
Know Your Profit Potential BEFORE You Trade!
I’m Chuck Hughes, ten-time trading champion and author of the coveted e-book, “Options Trading Made Easy”, the strategy guide that will teach you to calculate your trade’s profit potential before you risk any capital. Click here for a free copy now! pixel
Aerie Pharmaceuticals, Inc. (AERI)
Regulus (RGLS) Up on Top-Line Data from Kidney Disease Study
Why Aerie Pharmaceuticals Was Soaring So High This Week
Aerie set to be bought by Alcon for $770 million
See More Headlines

Receive AERI Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Aerie Pharmaceuticals and its competitors with MarketBeat's FREE daily newsletter.

AERI Company Calendar

Last Earnings
11/04/2021
Today
2/02/2023
Next Earnings (Estimated)
2/23/2023
Fiscal Year End
12/31/2023

Industry, Sector and Symbol

Industry
Biological products, except diagnostic
Sub-Industry
N/A
Sector
Medical
Current Symbol
NASDAQ:AERI
Employees
376
Year Founded
N/A

Price Target and Rating

Average Stock Price Forecast
$16.90
High Stock Price Forecast
$25.00
Low Stock Price Forecast
$14.00
Forecasted Upside/Downside
+10.8%
Consensus Rating
Hold
Rating Score (0-4)
2.00
Research Coverage
6 Analysts

Profitability

Net Income
$-74,810,000.00
Pretax Margin
-16.47%

Debt

Sales & Book Value

Annual Sales
$194.13 million
Book Value
($3.32) per share

Miscellaneous

Free Float
47,223,000
Market Cap
$753.61 million
Optionable
Optionable
Beta
-0.06

Key Executives

  • Mr. Raj Kannan (Age 58)
    CEO, Principal Financial Officer & Director
    Comp: $753.49k
  • Dr. Casey C. Kopczynski Ph.D. (Age 61)
    Co-Founder, Chief Innovation Officer & Head of Research and External Innovation
    Comp: $685.06k
  • Mr. John W. LaRocca Esq. (Age 57)
    Gen. Counsel & Sec.
    Comp: $676.62k
  • Mr. Peter F. Lang (Age 50)
    Chief Financial Officer
  • Dr. Michelle Senchyna Ph.D.
    Head of Clinical Devel. & Operations
  • Mr. Jeffrey M. Calabrese CPA (Age 55)
    VP of Fin. & Principal Accounting Officer
  • Ms. Carolyn McAuliffe
    Sr. Director of Communications
  • Ms. Wanda Francies
    Head of HR
  • Mr. Marvin J. Garrett (Age 71)
    Head of Regulatory Affairs & Quality Assurance
  • Mr. Craig R. Skenes
    Head of Bus. Devel.













AERI Stock - Frequently Asked Questions

Should I buy or sell Aerie Pharmaceuticals stock right now?

6 Wall Street research analysts have issued "buy," "hold," and "sell" ratings for Aerie Pharmaceuticals in the last year. There are currently 6 hold ratings for the stock. The consensus among Wall Street research analysts is that investors should "hold" AERI shares. A hold rating indicates that analysts believe investors should maintain any existing positions they have in AERI, but not buy additional shares or sell existing shares.
View AERI analyst ratings
or view top-rated stocks.

What is Aerie Pharmaceuticals' stock price forecast for 2023?

6 brokerages have issued 12-month price objectives for Aerie Pharmaceuticals' stock. Their AERI share price forecasts range from $14.00 to $25.00. On average, they expect the company's stock price to reach $16.90 in the next twelve months. This suggests a possible upside of 10.8% from the stock's current price.
View analysts price targets for AERI
or view top-rated stocks among Wall Street analysts.

When is Aerie Pharmaceuticals' next earnings date?

The company is scheduled to release its next quarterly earnings announcement on Thursday, February 23rd 2023.
View our AERI earnings forecast
.

How were Aerie Pharmaceuticals' earnings last quarter?

Aerie Pharmaceuticals, Inc. (NASDAQ:AERI) released its quarterly earnings data on Thursday, November, 4th. The company reported ($0.72) earnings per share for the quarter, missing the consensus estimate of ($0.62) by $0.10. The business earned $29.31 million during the quarter, compared to analysts' expectations of $29.13 million. During the same period last year, the business earned ($0.65) EPS.

What other stocks do shareholders of Aerie Pharmaceuticals own?

Based on aggregate information from My MarketBeat watchlists, some companies that other Aerie Pharmaceuticals investors own include Nicox (NICXF), Micron Technology (MU), Melinta Therapeutics (MLNT), BioMarin Pharmaceutical (BMRN), Gilead Sciences (GILD), Puma Biotechnology (PBYI), NVIDIA (NVDA), Wells Fargo & Company (WFC) and Alibaba Group (BABA).

What is Aerie Pharmaceuticals' stock symbol?

Aerie Pharmaceuticals trades on the NASDAQ under the ticker symbol "AERI."

Who are Aerie Pharmaceuticals' major shareholders?

Aerie Pharmaceuticals' stock is owned by a number of retail and institutional investors. Top institutional shareholders include Equitec Proprietary Markets LLC (0.00%) and Concourse Financial Group Securities Inc. (0.00%). Insiders that own company stock include Casey C Kopczynski and Gerald D Cagle.
View institutional ownership trends
.

What is Aerie Pharmaceuticals' stock price today?

One share of AERI stock can currently be purchased for approximately $15.25.

How much money does Aerie Pharmaceuticals make?

Aerie Pharmaceuticals (NASDAQ:AERI) has a market capitalization of $753.61 million and generates $194.13 million in revenue each year. The company earns $-74,810,000.00 in net income (profit) each year or ($0.77) on an earnings per share basis.

How many employees does Aerie Pharmaceuticals have?

The company employs 376 workers across the globe.

How can I contact Aerie Pharmaceuticals?

Aerie Pharmaceuticals' mailing address is 4301 Emperor Boulevard Suite 400, North Carolina NC, 27703. The official website for the company is www.aeriepharma.com. The company can be reached via phone at (919) 237-5300, via email at abavishi@aeriepharma.com, or via fax at 949-526-8787.

This page (NASDAQ:AERI) was last updated on 2/2/2023 by MarketBeat.com Staff